Key statistics
On Monday, Fractyl Health Inc (GUTS:NMQ) closed at 0.5019, 33.06% above the 52 week low of 0.3772 set on Feb 05, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.4589 |
|---|---|
| High | 0.5070 |
| Low | 0.4556 |
| Bid | 0.49 |
| Offer | 0.4947 |
| Previous close | 0.4693 |
| Average volume | 3.05m |
|---|---|
| Shares outstanding | 153.37m |
| Free float | 151.26m |
| P/E (TTM) | -- |
| Market cap | 76.98m USD |
| EPS (TTM) | -2.27 USD |
Data delayed at least 15 minutes, as of Mar 02 2026 21:00 GMT.
More ▼
- Fractyl Health Completes Randomization in REMAIN-1 Pivotal Cohort of Revita® for Post-GLP-1 Weight Maintenance
- Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation
- Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness
- Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category
- Fractyl Health Announces Call of Tranche A Warrants Tied to August 2025 Public Offering Following Achievement of Clinical and Trading Milestones
- Fractyl Health Reports Positive 6-Month REVEAL-1 Open-Label Results Showing Sustained Post-GLP-1 Weight Maintenance After a Single Revita® Procedure
- Fractyl Health to Participate in the 8th Annual Evercore Healthcare Conference
- Fractyl Health Reports Third Quarter 2025 Results; Revita® Clinical Momentum Builds Toward 2026 Pivotal Readout and PMA Filing, Cash Runway Extended into Early 2027
- Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025
- Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
More ▼
